2 active not recruiting, 1 not yet recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 2, Not yet recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Sapience Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP). ST316 IV - Familial Adenomatous Polyposis (FAP) | Phase 1 | Not yet recruiting | Sapience Therapeutics | 40 | 2027-01-04 | 2026-08-12 |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors ST316, FOLFIRI regimen & bevacizumab, Fruquintinib - Colon Cancer, Metastatic Colon Cancer | Phase 1 | Active not recruiting | Sapience Therapeutics | 130 | 2023-06-05 | 2026-07-22 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors ST101, Temozolomide, Radiation - Glioblastoma, Melanoma Stage IV | Phase 1 / Phase 2 | Active not recruiting | Sapience Therapeutics | 125 | 2020-07-01 | 2026-02-09 |
Adenomatous Polyposis Coli (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Colonic Neoplasms (1) · Desmoid Tumors (1) · Glioblastoma (1) · Melanoma (1) · Prostatic Neoplasms (1)
Bevacizumab (1) · HMPL-013 (1) · IFL protocol (1) · Radiation (1) · Temozolomide (1) · trifluridine tipiracil drug combination (1)
United States (2) · United Kingdom (1)
Abi Vainstein-Haras (1) · Abi Vainstein-Haras, MD (1)